Citigroup
MENS

Citigroup’s Jyong Biotech MENS Stock Holding History

Citigroup’s Portfolio MENS Stock Details MENS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.18K Sell
2,501
-286
-10% -$607 ﹤0.01% 5308
2026
Q1 		$5.99K Sell
2,787
-8,109
-74% -$19.8K ﹤0.01% 5212
2025
Q4 		$43K Buy
+10,896
New +$385K ﹤0.01% 4626

Other funds holding MENS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
HF
HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
CUAMC
China Universal Asset Management Company Shanghai, China $1.67B AUM 89% 1-Year Est. Return
SOW
State of Wyoming Cheyenne, Wyoming $989M AUM 52.24% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Citigroup's MENS Position: Q2 2026 in Review

Citigroup reduced its Jyong Biotech (MENS) stake by 10% in Q2 2026, selling an estimated $607 and leaving 2,501 shares worth $5.18K. The position accounts for ﹤0.01% of the portfolio, ranked #5308.

Citigroup first reported a position in MENS in Q4 2025 and has held it in 3 quarters since. The position peaked at $43K in Q4 2025. 19 funds tracked by Wall St. Rank hold MENS as of Q2 2026.

  • Citigroup held 2,501 shares of Jyong Biotech worth $5.18K as of Q2 2026.
  • Citigroup sold 286 Jyong Biotech shares in Q2 2026, an estimated $607.
  • Jyong Biotech made up ﹤0.01% of Citigroup's portfolio in Q2 2026, its #5308 holding.
  • Citigroup first reported a position in Jyong Biotech in Q4 2025 and has held it in 3 quarters since.
  • Citigroup's Jyong Biotech position peaked at $43K in Q4 2025.
  • 19 funds tracked by Wall St. Rank held Jyong Biotech as of Q2 2026.

Based on Citigroup's 13F filing for Q2 2026, filed 3 Aug 2026.